Expanded g-NK cells have enhanced in vitro ADCC activity proportionate to MM antigen expression. Comparison of the cytotoxicity of expanded g-NK and cNK cells (E:T, 0.5:1) against 6 MM cell lines with increasing CD38 (A-B) and SLAMF7 (C-D) expression in the presence or absence of 1 μg/mL daratumumab (anti-CD38) and 1 μg/mL elotuzumab (anti-SLAMF7), respectively (n = 5). The ADCC of g-NK cells when combined with daratumumab or elotuzumab is proportionate to myeloma CD38 (B) or SLAMF7 (D) expression, respectively. To compare cytotoxicity against MM cells between expanded g-NK, g-NK plus antibody, cNK, and cNK plus antibody, a one-way ANOVA was performed with Bonferroni post hoc testing to determine differences between individual categories. Pearson R² values were used to assess the correlation between ADCC and antigen expression. Values are mean ± SEM. ***P < .001. MFI, mean fluorescence intensity.